Histone Code Modifier EHMT2: Potential Drug Target Or Biomarker

Target Name: EHMT2

NCBI ID: G10919

EHMT2

Histone Code Modifier EHMT2: Potential Drug Target Or Biomarker

Histone-lysine N-methyltransferase EHMT2 (isoform b), also known as HLTN3, is a enzyme involved in the histone code in eukaryotic cells. It is a key player in the regulation of gene expression and is associated with various cellular processes, including cell growth, differentiation, and response to stimuli. EHMT2 has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, it has potential as a drug target or biomarker.

The histone code is a system of genetic instructions that is used to store and transmit genetic information from one generation to the next. The histone-lysine N-methyltransferase EHMT2 is a key enzyme that modifies the histone code by adding a methyl group to specific lysine residues. This modification has a significant impact on the stability and accessibility of the histones, and is involved in the regulation of various cellular processes.

EHMT2 is a 21-kDa protein that is expressed in a variety of tissues and cells, including muscle, liver, and brain. It is highly homogeneous and has a calculated pI of 2.8, which makes it a good candidate for drug targeting. EHMT2 has been shown to play a role in the regulation of gene expression by modifying the accessibility of specific mRNAs. It has been shown to interact with a variety of protein partners, including histone modifications, transcription factors, and splicing factors.

EHMT2 has been shown to be involved in the regulation of cellular processes that are important for human health and disease. For example, EHMT2 has been shown to be involved in the regulation of cell growth and differentiation. It has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of EHMT2 are associated with poor prognosis in breast cancer. Additionally, EHMT2 has been shown to be involved in the regulation of inflammation, and has been shown to play a role in the development of neuroinflammatory diseases.

EHMT2 has also been shown to be a potential drug target. Several studies have shown that inhibiting EHMT2 can lead to therapeutic effects in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, studies have shown that inhibiting EHMT2 can lead to a reduction in the growth and spread of cancer cells. Additionally, inhibiting EHMT2 has been shown to protect against neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In conclusion, EHMT2 is a protein that is involved in the regulation of the histone code and has been shown to play a role in various cellular processes. It is a potential drug target or biomarker and has the potential to be used to treat a variety of diseases. Further research is needed to fully understand the role of EHMT2 in cellular processes and its potential as a drug target or biomarker.

Protein Name: Euchromatic Histone Lysine Methyltransferase 2

Functions: Histone methyltransferase that specifically mono- and dimethylates 'Lys-9' of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin. H3K9me represents a specific tag for epigenetic transcriptional repression by recruiting HP1 proteins to methylated histones. Also mediates monomethylation of 'Lys-56' of histone H3 (H3K56me1) in G1 phase, leading to promote interaction between histone H3 and PCNA and regulating DNA replication. Also weakly methylates 'Lys-27' of histone H3 (H3K27me). Also required for DNA methylation, the histone methyltransferase activity is not required for DNA methylation, suggesting that these 2 activities function independently. Probably targeted to histone H3 by different DNA-binding proteins like E2F6, MGA, MAX and/or DP1. May also methylate histone H1. In addition to the histone methyltransferase activity, also methylates non-histone proteins: mediates dimethylation of 'Lys-373' of p53/TP53. Also methylates CDYL, WIZ, ACIN1, DNMT1, HDAC1, ERCC6, KLF12 and itself

The "EHMT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EHMT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets